David: It is hard to estimate the time horizon for CYGX. The only thing that I am pretty sure about is that the stock price is on an upward trajectory. There will be pull backs, as there always are. Nothing moves up in a straight line. But, realistically I anticipate that we cross $2.00 a share by year end, and that is pretty conservative. I think $5 a share by the end of 2007 is realistic. The major thing holding them back is the lack of money. For all they have accomplished the real failure of management has been it's failure to secure adequate funding. They need $10 million to start, in order to build out the entire synDNA production facility and to complete the FDA paperwork and get an IND for the herpes compound and the staph aureus antibacterial compund. They are not advancing their science quickly enough. It will be obsolete before they ever get it through 3 phases of FDA scrutiny. Still, you have to respect the opinions of people and companies with more knowledge and experience than any of us on this board possess. If Aldevron and GE HEalthcare are interested in what CYGX has, who am I to argue. That alone is reason to hold the stock and to buy more on weakness until an investor has as much as he or she wants to invest. Even after the share price increases we've seen since December, the downside on the stock is still only @ $1.25 and the upside is well above that. Of the biotech stocks I follow only Peregrine (PPHM) has a comparable risk/reward benefit, with a very shallow down side and an huge potential upside. So if you are looking at a quick buck, CYGX will probably frustrate you. It is a stock to hold, with patience, for the long term. I have a substantial amount, for me, of 210 K shares. After some short term drops in some of my other stocks it represents 16-17% of my investment portfolio at the present time. So I believe in the company over the long term.
